Evidence map›Paper›PMID 38430393›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2024

Systematic and quantitative analysis of stop codon readthrough in Rett syndrome nonsense mutations.

Dennis Lebeda, Adrian Fierenz, Lina Werfel, Rina Rosin-Arbesfeld, Julia Hofhuis, Sven Thoms

Open access · hybridAbstract read
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. RiboScreenBiomedicines · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Dennis LebedaDepartment for Biochemistry and Molecular Medicine, Medical School EWL, Bielefeld University, Bielefeld, Germany.ORCID 0009-0006-3535-2163
Adrian FierenzDepartment of Child and Adolescent Health, University Medical Center Göttingen, Göttingen, Germany.
Lina WerfelDepartment of Child and Adolescent Health, University Medical Center Göttingen, Göttingen, Germany.
Rina Rosin-ArbesfeldDepartment of Clinical Microbiology and Immunology, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Julia HofhuisDepartment for Biochemistry and Molecular Medicine, Medical School EWL, Bielefeld University, Bielefeld, Germany.
Sven ThomsDepartment for Biochemistry and Molecular Medicine, Medical School EWL, Bielefeld University, Bielefeld, Germany. sven.thoms@uni-bielefeld.de.ORCID 0000-0003-3018-6363
Bielefeld University · DEMedizinische Hochschule Hannover · DETel Aviv University · ILUniversitätsmedizin Göttingen · DE

Funding

Deutsche Forschungsgemeinschaft SFB 1002/3 TP A10Deutsche Forschungsgemeinschaft TH 1538/3Eva Luise und Horst Köhler Stiftung Research Award 2016German-Israeli Foundation for Scientific Research and Development 1459
6 · The paper itself

Abstract

Rett syndrome (RTT) is a neurodevelopmental disorder resulting from genetic mutations in the methyl CpG binding protein 2 (MeCP2) gene. Specifically, around 35% of RTT patients harbor premature termination codons (PTCs) within the MeCP2 gene due to nonsense mutations. A promising therapeutic avenue for these individuals involves the use of aminoglycosides, which stimulate translational readthrough (TR) by causing stop codons to be interpreted as sense codons. However, the effectiveness of this treatment depends on several factors, including the type of stop codon and the surrounding nucleotides, collectively referred to as the stop codon context (SCC). Here, we develop a high-content reporter system to precisely measure TR efficiency at different SCCs, assess the recovery of the full-length MeCP2 protein, and evaluate its subcellular localization. We have conducted a comprehensive investigation into the intricate relationship between SCC characteristics and TR induction, examining a total of 14 pathogenic MeCP2 nonsense mutations with the aim to advance the prospects of personalized therapy for individuals with RTT. Our results demonstrate that TR induction can successfully restore full-length MeCP2 protein, albeit to varying degrees, contingent upon the SCC and the specific position of the PTC within the MeCP2 mRNA. TR induction can lead to the re-establishment of nuclear localization of MeCP2, indicating the potential restoration of protein functionality. In summary, our findings underscore the significance of SCC-specific approaches in the development of tailored therapies for RTT. By unraveling the relationship between SCC and TR therapy, we pave the way for personalized, individualized treatment strategies that hold promise for improving the lives of individuals affected by this debilitating neurodevelopmental disorder. KEY MESSAGES: The efficiency of readthrough induction at MeCP2 premature termination codons strongly depends on the stop codon context. The position of the premature termination codon on the transcript influences the readthrough inducibility. A new high-content dual reporter assay facilitates the measurement and prediction of readthrough efficiency of specific nucleotide stop contexts. Readthrough induction results in the recovery of full-length MeCP2 and its re-localization to the nucleus. MeCP2 requires only one of its annotated nuclear localization signals.

Indexed as

Codon, NonsenseCodon, TerminatorMethyl-CpG-Binding Protein 2Rett SyndromeHEK293 CellsHumansProtein BiosynthesisRNA, MessengerCodon, NonsenseCodon, TerminatorMECP2 protein, humanMethyl-CpG-Binding Protein 2RNA, MessengerAminoglycosideMeCP2Personalized medicineRare diseaseRett syndromeTranslational readthrough

Identifiers

PMID38430393
PMCPMC11055764
OpenAlexW4392346122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.